In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant ...

Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte ...

About Myasthenia Gravis. Myasthenia Gravis (MG) is a rare neurological disorder that severely impairs muscle movement and can lead to life-threatening complications.

Its growth is attributed to the anticipated launch of seven late-stage pipeline therapies. The myasthenia gravis (MG) market ...

Abstract. Background Comorbid autoimmune disorders affect approximately 0.2% of the population.A second autoimmune disease occurs in up to 15% of myasthenia gravis (MG) patients. Objective To evaluate ...

Myasthenia Gravis (MG) is an autoimmune neuromuscular junction disorder that results in fatigue and fluctuating weakness. The incidence of MG varies according to sex, age, and ethnic group 1-6, with ...

Myasthenia gravis (MG) should be subgrouped into early-onset, late-onset, thymoma, ocular, anti-MuSK, anti-LRP4 and antibody-negative MG. MG has a prevalence of 140 per million, and an annual ...

Background Myasthenia Gravis (MG) is an autoimmune disorder presenting with fatigable muscle weakness leading to potential respiratory distress. Clinical management aims to improve patient quality of ...

Myasthenia gravis affects both men and women and occurs across all races and ethnicities. Its incidence and prevalence are higher in women under age 50 and in men ages 65 and older.

People with generalized myasthenia gravis (MG) experience psychiatric symptoms including anxiety, depression, and post-traumatic stress disorder (PTSD) at rates higher than that of the general ...

The NHS webpage on myasthenia gravis may be a good place to find out more. These organisations can give you advice and support: Myaware, 01332 290 219; Muscular Dystrophy UK, 0800 652 6352; You can ...

Evidence-based recommendations on efgartigimod (Vyvgart) for treating antibody-positive generalised myasthenia gravis in adults.. Last reviewed: 04 June 2025 Next review: This guidance will be ...